Physician profile
Maria C Ospina
NPI 1881633212
$2,111,823.66
in general payments reported to CMS, 2019-2025
51 companies · $547K in 2025
The $547K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182K · 2020: $129K · 2021: $231K · 2022: $386K · 2023: $307K · 2024: $330K · 2025: $547K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $499K · Honoraria: $320K · Consulting Fee: $203K · Travel and Lodging: $127K · Food and Beverage: $27K · Education: $8,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $498,557.17 |
| Honoraria | $320,467.39 |
| Consulting Fee | $203,005.54 |
| Travel and Lodging | $127,026.44 |
| Food and Beverage | $26,787.17 |
| Education | $8,187.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $642,958.04 | 2019-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $415,562.99 | 2019-2025 | Crexont, Rytary, Ongentys |
| Mdd US Operations, LLC | $290,818.39 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Abbvie INC. | $268,935.44 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $254,056.50 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Kyowa Kirin, INC. | $95,116.04 | 2020-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $52,343.10 | 2024-2025 | Inbrija, Xeomin, Ampyra |
| Acorda Therapeutics, INC | $51,272.64 | 2019-2024 | Inbrija |
| Sunovion Pharmaceuticals INC. | $9,484.22 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $8,912.57 | 2019-2021 | |
| Boston Scientific Corporation | $5,800.23 | 2019-2025 | Vercise, General - Dbs |
| Medtronic, INC. | $4,454.97 | 2021-2025 | Percept Pc Brainsense, Sensight |
| Abbott Laboratories | $4,149.90 | 2019-2025 | Infinity, Proclaim |
| Acadia Pharmaceuticals INC | $3,421.23 | 2019-2025 | Nuplazid |
| Medtronic USA, INC. | $1,005.37 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Ospina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.